Logo Certara, Inc.

Certara, Inc. (CERT) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Certara, Inc. · Health Care · ref. ETF XLV · 50 calls · price $9.6
🏆JPI 2026 portfoliosSee tracking →
What the company does: Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.

📈 Certara, Inc. (CERT) stock price

$9.6-19.3% over range
Oct 14, 25low $4.48 · high $12.72Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
25% recommend buying · 8 analysts
📊 JPI status : Certara, Inc. has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →
⚠️ The stock trades above the median target: it has beaten expectations. The “Hold” reflects conviction on the company, but the remaining quantified upside is low/negative.

🎯 CERT price target & analyst consensus — price $9.60

The price target · all analysts combined (8 targets)
Highest target · 1 firm of 8$10+4.2%
Median target · of 8 targets$9-6.2%
Lowest target · 2 firms of 8$6-37.5%
Current price$9.6
Where these 8 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 338% $10 ↔ $11
Below 563% $6 ↔ $9
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 59% of its targets hit on this sector (76 calls tested). It aims for $10 (+4.2 %), call made on October 1, 2026, maturing on October 1, 2027 (13 d ago).

The 1 reliable analyst $10+4.2 %
The 7 other firms $9-6.2 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $10 median. “The 7 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 8 ratings (last 6 months)
Strong Buy00%
Buy225%
Hold675%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Certara, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on CERT

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
UBS ↗ 50% -11.1% 2
Barclays ↗ 22% -17.2% 9
Credit Suisse 0% -14.9% 5
SVB Leerink 0% -15.5% 2
Piper Sandler ↗ 0% -17.8% 2
B of A Securities ↗ 0% -25.9% 2
Stephens & Co. ↗ 0% -26.7% 3
Keybanc ↗ 0% -39.6% 5

📊 What $1,000 invested in Certara, Inc. would be worth › open the full page

In short — $1,000 invested in Certara, Inc. 10 years ago would be worth $175 today, i.e. -25%/yr on average. Best year: 2023 (+9%), worst: 2022 (-43%). Price performance, excluding dividends.

If I'd invested $1,000 in Certara, Inc.

InvestmentWorth todayGain
1 years ago$595-40%
3 years ago$415-58%
5 years ago$198-80%
→ See Certara, Inc.'s full return history + gain calculator

Return by year (Certara, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)-24%$763 (-24%)
2025-22%$595 (-40%)
2024-36%$379 (-62%)
→ See Certara, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Certara, Inc.

Loading news…

📋 All analyst calls on CERT

TD Cowen ↗
Oct 13, 26
▲ Buy · 🎯$11
Today : $9.6 — upside +15%
🎯 on CERT : no call matured yet · 📊 on Health : 50% · -1.0% (40 calls)
in progress (365j)
matures : Oct 13, 27
Barclays ↗
Oct 7, 26
■ Equal-Weight neutral · not a buy · 🎯$9
Price at call : $8.64 — gap to target +4%
Today : $9.6 — gap to target -6%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Oct 7, 27
UBS ↗
Sep 30, 26
■ Neutral neutral · not a buy · 🎯$10
Price at call : $9.34 — gap to target +7%
Today : $9.6 — gap to target +4%
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Sep 30, 27
Barclays ↗
Aug 5, 26
■ Equal-Weight neutral · not a buy · 🎯$7.5
Price at call : $8.01 — gap to target -6%
Today : $9.6 — gap to target -22%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Aug 5, 27
Craig-Hallum ↗
May 12, 26
■ Hold neutral · not a buy · 🎯$8
Price at call : $4.79 — gap to target +67%
Today : $9.6 — gap to target -17%
🎯 on CERT : 0% (1 call matured) · 📊 on Health : 52% · +14.5% (25 calls)
in progress (365j)
matures : May 12, 27
BMO Capital ↗
May 12, 26
■ Market Perform neutral · not a buy · 🎯$6
Price at call : $4.79 — gap to target +25%
Today : $9.6 — gap to target -38%
🎯 on CERT : no call matured yet · 📊 on Health : 43.3% · -2.2% (67 calls)
in progress (365j)
matures : May 12, 27
Barclays ↗
May 12, 26
■ Equal-Weight neutral · not a buy · 🎯$6.5
Price at call : $4.79 — gap to target +36%
Today : $9.6 — gap to target -32%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : May 12, 27
Stephens & Co. ↗
May 12, 26
▲ Overweight · 🎯$9
Price at call : $4.79 — upside +88%
Today : $9.6 — upside -6%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
in progress (365j)
matures : May 12, 27
See the other 42 calls, newest to oldest
Morgan Stanley ↗
May 12, 26
■ Equal-Weight neutral · not a buy · 🎯$10
Price at call : $5.09 — gap to target +96%
Today : $9.6 — gap to target +4%
🎯 on CERT : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : May 12, 27
Baird ↗
May 12, 26
■ Neutral neutral · not a buy · 🎯$6
Price at call : $5.09 — gap to target +18%
Today : $9.6 — gap to target -38%
🎯 on CERT : no call matured yet · 📊 on Health : 38.1% · -2.9% (84 calls)
in progress (365j)
matures : May 12, 27
Keybanc ↗
Apr 13, 26
▲ Overweight · 🎯$8
Price at call : $5.79 — upside +38%
Today : $9.6 — upside -17%
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
in progress (365j)
matures : Apr 13, 27
Barclays ↗
Mar 6, 26
■ Equal-Weight neutral · not a buy · 🎯$8
Price at call : $7.06 — gap to target +13%
Today : $9.6 — gap to target -17%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Mar 6, 27
Barclays ↗
Feb 27, 26
▲ Overweight · 🎯$8
Price at call : $7.05 — upside +13%
Today : $9.6 — upside -17%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Feb 27, 27
Keybanc ↗
Jan 8, 26
▲ Overweight · 🎯$12
Price at call : $9.67 — upside +24%
Today : $9.6 — upside +25%
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
in progress (365j)
matures : Jan 8, 27
▲ Outperform · 🎯$13
Price at call : $9.49 — upside +37%
Today : $9.6 — upside +35%
🎯 on CERT : no call matured yet · 📊 on Health : 54.5% · +7.0% (11 calls)
in progress (365j)
matures : Jan 6, 27
Morgan Stanley ↗
Dec 18, 25
■ Equal-Weight neutral · not a buy · 🎯$12
Price at call : $9.07 — gap to target +32%
Today : $9.6 — gap to target +25%
🎯 on CERT : no call matured yet · 📊 on Health : 55.5% · +4.6% (182 calls)
in progress (365j)
matures : Dec 18, 26
Barclays ↗
Dec 15, 25
▲ Overweight · 🎯$13
Price at call : $8.66 — upside +50%
Today : $9.6 — upside +35%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Dec 15, 26
Stephens & Co. ↗
Dec 12, 25
▲ Overweight · 🎯$12
Price at call : $8.58 — upside +40%
Today : $9.6 — upside +25%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
in progress (365j)
matures : Dec 12, 26
BMO Capital ↗
Nov 13, 25
■ Market Perform neutral · not a buy · 🎯$9
Price at call : $8.41 — gap to target +7%
Today : $9.6 — gap to target -6%
🎯 on CERT : no call matured yet · 📊 on Health : 43.3% · -2.2% (67 calls)
in progress (365j)
matures : Nov 13, 26
Barclays ↗
Nov 7, 25
▲ Overweight · 🎯$14
Price at call : $8.62 — upside +62%
Today : $9.6 — upside +46%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Nov 7, 26
Keybanc ↗
Oct 8, 25
▲ Overweight · 🎯$16
Price at call : $13 — upside +23%
Today : $9.6 — upside +67%
Expected +23% · Actual -34% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
-33.5%
stock -34% · XLV +16%
matured Oct 8, 26
Barclays ↗
Oct 2, 25
▲ Overweight · 🎯$16
Price at call : $13.07 — upside +22%
Today : $9.6 — upside +67%
Expected +22% · Actual -23% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
-22.9%
stock -23% · XLV +16%
matured Oct 2, 26
Craig-Hallum ↗
Sep 29, 25
▲ Buy · 🎯$16
Price at call : $12.22 — upside +31%
Today : $9.6 — upside +67%
Expected +31% · Actual -25% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (1 call matured) · 📊 on Health : 52% · +14.5% (25 calls)
-24.7%
stock -25% · XLV +21%
matured Sep 29, 26
UBS ↗
Aug 7, 25
▲ Buy · 🎯$15
Price at call : $10.94 — upside +37%
Today : $9.6 — upside +56%
Expected +37% · Actual -26% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
-26.2%
stock -26% · XLV +29%
matured Aug 7, 26
Keybanc ↗
Jul 14, 25
▲ Overweight · 🎯$15
Price at call : $11.14 — upside +35%
Today : $9.6 — upside +56%
Expected +35% · Actual -40% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
-40.1%
stock -40% · XLV +17%
matured Jul 14, 26
Barclays ↗
May 8, 25
▲ Overweight · 🎯$14
Price at call : $11.98 — upside +17%
Today : $9.6 — upside +46%
Expected +17% · Actual -57% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
-57.2%
stock -57% · XLV +8%
matured May 8, 26
■ Market Perform neutral · not a buy
🎯 on CERT : no call matured yet · 📊 unranked overall
in progress (365j)
matures : May 6, 26
Keybanc ↗
Apr 16, 25
▲ Overweight · 🎯$18
Price at call : $13.53 — upside +33%
Today : $9.6 — upside +88%
Expected +33% · Actual -54% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
-54.5%
stock -54% · XLV +8%
matured Apr 16, 26
Baird ↗
Apr 11, 25
■ Neutral neutral · not a buy · 🎯$13
Price at call : $12.91 — gap to target +1%
Today : $9.6 — gap to target +35%
🎯 on CERT : no call matured yet · 📊 on Health : 38.1% · -2.9% (84 calls)
in progress (365j)
matures : Apr 11, 26
Barclays ↗
Apr 10, 25
■ Equal-Weight neutral · not a buy · 🎯$11
Price at call : $12.91 — gap to target -15%
Today : $9.6 — gap to target +15%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Apr 10, 26
Barclays ↗
Feb 28, 25
■ Equal-Weight neutral · not a buy · 🎯$13
Price at call : $11.94 — gap to target +9%
Today : $9.6 — gap to target +35%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Feb 28, 26
Stephens & Co. ↗
Feb 27, 25
▲ Overweight · 🎯$17
Price at call : $11.98 — upside +42%
Today : $9.6 — upside +77%
Expected +42% · Actual -41% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
-41.1%
stock -41% · XLV +6%
matured Feb 27, 26
Barclays ↗
Nov 7, 24
■ Equal-Weight neutral · not a buy · 🎯$12
Price at call : $11.03 — gap to target +9%
Today : $9.6 — gap to target +25%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Nov 7, 25
Baird ↗
Nov 5, 24
■ Neutral neutral · not a buy · 🎯$13
Price at call : $10.31 — gap to target +26%
Today : $9.6 — gap to target +35%
🎯 on CERT : no call matured yet · 📊 on Health : 38.1% · -2.9% (84 calls)
in progress (365j)
matures : Nov 5, 25
Barclays ↗
Oct 15, 24
■ Equal-Weight neutral · not a buy · 🎯$14
Price at call : $11.22 — gap to target +25%
Today : $9.6 — gap to target +46%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Oct 15, 25
UBS ↗
Sep 27, 24
▲ Buy · 🎯$16
Price at call : $11.71 — upside +37%
Today : $9.6 — upside +67%
Expected +37% · Actual +4% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
+4.0%
stock +4% · XLV -12%
matured Sep 27, 25
UBS ↗
Aug 7, 24
■ Neutral neutral · not a buy · 🎯$16
Price at call : $13.07 — gap to target +22%
Today : $9.6 — gap to target +67%
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Aug 7, 25
Baird ↗
Aug 7, 24
■ Neutral neutral · not a buy · 🎯$18
Price at call : $13.07 — gap to target +38%
Today : $9.6 — gap to target +88%
🎯 on CERT : no call matured yet · 📊 on Health : 38.1% · -2.9% (84 calls)
in progress (365j)
matures : Aug 7, 25
Keybanc ↗
Jul 11, 24
▲ Overweight · 🎯$20
Price at call : $15.12 — upside +32%
Today : $9.6 — upside +108%
Expected +32% · Actual -27% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
-26.7%
stock -27% · XLV -8%
matured Jul 11, 25
JMP Securities
Jul 10, 24
■ Market Perform neutral · not a buy
🎯 on CERT : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Jul 10, 25
Barclays ↗
Jun 28, 24
■ Equal-Weight neutral · not a buy · 🎯$16
Price at call : $13.64 — gap to target +17%
Today : $9.6 — gap to target +67%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Jun 28, 25
Keybanc ↗
Apr 10, 24
▲ Overweight · 🎯$23
Price at call : $18.46 — upside +25%
Today : $9.6 — upside +140%
Expected +25% · Actual -43% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
-43.1%
stock -43% · XLV -5%
matured Apr 10, 25
■ Market Perform neutral · not a buy
🎯 on CERT : no call matured yet · 📊 unranked overall
in progress (365j)
matures : Apr 4, 25
UBS ↗
Mar 1, 24
■ Neutral neutral · not a buy · 🎯$20
Price at call : $18.88 — gap to target +6%
Today : $9.6 — gap to target +108%
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Mar 1, 25
Jefferies ↗
Mar 1, 24
■ Hold neutral · not a buy · 🎯$15.5
Price at call : $18.3 — gap to target -15%
Today : $9.6 — gap to target +61%
🎯 on CERT : no call matured yet · 📊 on Health : 49.6% · +9.4% (137 calls)
in progress (365j)
matures : Mar 1, 25
■ Market Perform neutral · not a buy · 🎯$19
Price at call : $16.86 — gap to target +13%
Today : $9.6 — gap to target +98%
🎯 on CERT : no call matured yet · 📊 on Health : 54.5% · +7.0% (11 calls)
in progress (365j)
matures : Feb 25, 25
Barclays ↗
Jan 25, 24
■ Equal-Weight neutral · not a buy · 🎯$18
Price at call : $16.62 — gap to target +8%
Today : $9.6 — gap to target +88%
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 37% · -8.6% (154 calls)
in progress (365j)
matures : Jan 24, 25
UBS ↗
Dec 7, 23
■ Neutral neutral · not a buy · 🎯$17
Price at call : $16.1 — gap to target +6%
Today : $9.6 — gap to target +77%
🎯 on CERT : 50% (2 calls matureds) · 📊 on Health : 48.7% · +2.2% (76 calls)
in progress (365j)
matures : Dec 6, 24
Keybanc ↗
Dec 5, 23
■ Sector Weight neutral · not a buy
🎯 on CERT : 0% (5 calls matureds) · 📊 on Health : 23.6% · -18.3% (110 calls)
in progress (365j)
matures : Dec 4, 24
Stephens & Co. ↗
Oct 11, 23
▲ Overweight · 🎯$20
Price at call : $14.28 — upside +40%
Today : $9.6 — upside +108%
Expected +40% · Actual -19% · Reason (≥ +15%) : ✗ No
🎯 on CERT : 0% (2 calls matureds) · 📊 on Health : 44.3% · +2.1% (88 calls)
-18.9%
stock -19% · XLV +17%
matured Oct 10, 24

Frequently asked questions

Should I buy Certara, Inc. stock?

This isn't buy advice. For Certara, Inc., the analyst consensus is "Hold", with an average price target of $9.00 (-6% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 50% of the time (2 calls tracked on Certara, Inc.). We show the numbers — you decide.

Is it too late to buy Certara, Inc.? How high can it go?

The most bullish analyst target on Certara, Inc. is $10.00 (+4% above today's price); the average is $9.00. That's the upside they see. Check how reliable those analysts have actually been on Certara, Inc. on our site before trusting it.

Is Certara, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 8 analysts have a real record on Certara, Inc., the best hitting 50% over 2 calls. Current consensus: "Hold". Make your call on data, not noise.

Should you invest in Certara, Inc.? The case for and against

The arguments for and against, one by one, from the numbers: why invest in CERT (and why hesitate).

What has Certara, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: CERT performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)